PILOT STUDY PROPOSAL FOR EARLY DISCHARGE OF LOW-RISK NEUTROPENIC PATIENTS
|
|
- Alexis Johnston
- 5 years ago
- Views:
Transcription
1 PILOT STUDY PROPOSAL FOR EARLY DISCHARGE OF LOW-RISK NEUTROPENIC PATIENTS RATIONALE: It is increasingly being recognised that not all neutropenic patients have the same risk of complications during episodes of febrile neutropenia. A group of low risk patients can be reliably identified and the intensity of their treatment safely reduced allowing early discharge with significant reductions in length of stay and cost (1). Importantly identifying low risk patients also highlights the high-risk group whose mortality rate is 15% allowing these patients to be managed aggressively from an earlier stage. Currently 5-10 patients with neutropenic sepsis are admitted to the RUH per month from a variety of sources (oncology outpatients, day unit, MAU, A+E). A retrospective look at 15 patients documented in the William Budd outlier book admitted with neutropenic sepsis between 1 st April and 26 th June 2008 showed they had an average bed stay of 5.6 days but that 7 of them might have been suitable for early discharge on oral antibiotics, thereby freeing up beds with significant cost savings. The MASCC index was first developed in 2000 by Klastersky et al (2) to identify low risk patients and has been prospectively validated in a multinational trial (3) with a positive predictive value of 91%, specificity of 68% and sensitivity of 71%. A trial of early discharge in 102 low risk patients at Clatterbridge (4) showed similar efficacy between the oral and iv antibiotic arms with resolution of fever with 1 st line antibiotics in 84.8 and 90% of patients respectively (p=0.55). Only 1 patient deteriorated significantly in the oral antibiotic group and this occurred in the initial 24 hr in-patient assessment period. 5 patients in the oral antibiotic arm required re-admission for 2 nd line iv antibiotics, with no deaths in either arm. Although the MASCC score was published after this trial began the authors retrospectively scored their patients using it and found >95% of their trial patients fitted this definition of low risk. Many centres both in the UK and abroad are now tailoring treatment of neutropenic sepsis rather than having a blanket approach and are using oral antibiotics 1 st line in low risk patients followed by early discharge at 24 hours for those patients who remain clinically stable. PROPOSAL: A 3 month pilot study introducing the MASCC index for stratifying risk of complications for all patients presenting with febrile neutropenia after chemotherapy. All low risk patients would then receive oral antibiotics (Augmentin + Ciprofloxacin) unless penicillin allergic, from time of admission. At 24 hours those patients fitting discharge criteria would be reviewed by an oncology or haematology SpR or consultant and discharged home on oral antibiotics for follow up in the oncology day unit 48 hours after discharge. The oncology/ haematology team would also be responsible for following up outstanding blood culture results. High risk patients would continue to receive iv antibiotics from the outset but we would envisage that anyone unable to be discharged home at 24 hours should then be prioritised for transfer to William Budd ward. REFERENCES 1
2 1) Vidal.L, Paul.M, Ben-Dor.I, Soares-Weiser.K, Leibovici.L. Oral versus intravenous antibiotic treatment for febrile neutropaenia in cancer patients. Cochrane Database of Systematic Reviews 2004 Issue 4. Art. No.: CD DOI: / CD pub2. 2) Klastersky.J. Management of Fever in Neutropenic Patients with Different Risks of Complications. CID 2004:39(suppl 1)S ) Klastersky.J et al. The Multinational Association for Supportive Care in Cancer Risk Index: A Multinational Scoring System for Identifying Low-Risk Febrile Neutropenic Cancer Patients. JCO (16) ) Innes.H, Smith.D, O Reilly.S, Clark, P, Kelly.V, Marshall.E. Oral antibiotics with early discharge compared with in-patient intravenous antibiotics in patients with cancer: a prospective randomised controlled single centre study. BJC ;
3 Procedure for Treating Patients with Low Risk Febrile Neutropenia 1. Admit and use MASCC score to assign risk status. Patients who have a clearly evident source of infection such as an abscess, cellulitis, diarrhoea, pneumonia or line infection should be given antibiotics appropriate to this site. The admitting doctor should also check to see whether there have been any recent positive microbiology results which might influence choice of antibiotic. Patients who are penicillin allergic or who have received ciprofloxacin as prophylaxis should not be treated with the oral combination. 2. If there is any doubt as to the suitability of the patient for oral antibiotic therapy and early discharge they should be treated as severe with iv antibiotics. This can also be discussed with a haematologist, oncologist or microbiologist 3. Patients being treated with the expectation that they will be discharged home after 24 hrs should remain on MAU. 4. William Budd ward should be informed of all admissions for neutropenic sepsis immediately by faxing the MASCC score sheet to All low risk patients (on oral antibiotics) are reviewed at approximately 24 hours by a haematology or oncology SpR/ consultant and are discharged home if appropriate, with a patient information sheet. High risk patients and those no longer suitable for early discharge should be transferred to William Budd as soon as possible. 6. The haematologist/ oncologist who reviews the patient is responsible for checking all culture results and arranging to see the patient at 48 hours on the oncology day unit (ideally in the morning). 7. Patients, in whom there has been any deterioration, should be re-admitted, preferably to William Budd ward. 3
4 Guidelines for the Treatment of Neutropenic Fever in Low Risk Patients This guideline is for low risk neutropenic patients (neutrophils <1x10 9 /L) who have a temperature 38 C. Repeated temperatures between 37.5 C and 38 C in a neutropenic patient may also be of clinical significance and should not be ignored. Severely shocked patients maybe hypothermic. Use the MASCC Index below to categorise patients into Severe or Non-severe. Acute leukaemia, Burkitts lymphoma, Allograft and Autograft patients are all treated as severe. Patients classed as severe should receive IV antibiotics as per the existing RUH protocol. MASCC Index: (Journal of Clinical Oncology 18: , 2000) Characteristic Score Age 60 years 0 < 60 years 2 Patient dehydrated, requiring fluids? No 3 Yes 0 Patient hypotensive? Systolic BP <90 0 Systolic BP 90 5 Does patient have COPD? Yes 0 (Chronic obstructive pulmonary disease) No 4 Does the patient have a solid tumour or no history Yes 4 of previous fungal infection? No 0 Does the patient have symptoms related to this None or mild symptoms 5 febrile neutropenic episode? Moderate symptoms 3 Severe symptoms 0 Was the patient already an inpatient? Already an inpatient 0 Admitted with this episode 3 If score 21 treat as non-severe. If in any doubt treat as severe. Criteria for oral antibiotic treatment: patients must fulfil all criteria MASCC score > 21 And no evidence of focal infection such as cellulitis, abscess, pneumonia, line infection And no diarrhoea or recent C.difficile infection And no allergy to penicillin or ciprofloxacin And no recent positive microbiology culture results suggesting that co-amoxiclav/ ciprofloxacin combination would be inappropriate And patient has not received prophylaxis with ciprofloxacin within last 28 days Patients not fitting above criteria should receive iv antibiotics as per the existing RUH protocol for neutropenic sepsis Oral Antibiotic treatment: Co-amoxiclav 625mg po tds + Ciprofloxacin 750mg po bd for 7 days Discharge criteria for non-severe patients: The discharge review must be carried out by a haematology or oncology SpR or consultant. Clinically stable and symptomatically improved, irrespective of neutrophil count Fever 37.9 o C on 3 occasions over a 24 hour period The patient must give a history of good compliance and must be willing to return to the ward at short notice in the event of antibiotic intolerance or clinical deterioration 4
5 Oral (Tablet) Antibiotics For Neutropenic Fever During Chemotherapy Patient Information Sheet You are going home with tablet antibiotics to treat your infection. We know this is sensible and safe practice, and of benefit to patients. However occasionally patients need to return to hospital for antibiotics through a drip. If you experience any of the following please phone William Budd ward on or immediately: o Vomiting e.g. Unable to drink a glass of water or vomiting more than 4 times in 24 hours o Rash or other concerns about allergy to antibiotic tablets o Diarrhoea e.g. more than 4 loose stools in 24 hours o Temperature more than 38 o C for an hour o Feeling much less well than when you left the ward. You will be seen on William Budd Day Unit approximately 48 hours after discharge. However please don t wait for this appointment if you have any of the above symptoms. Please phone for advice if you have any other concerns or worries In the event you are unwell and need to come back into hospital, we will do our best to admit you to William Budd ward. Please take this information with you if you attend another hospital/unit. The antibiotic policy is available for your doctor on the RUH intranet. Discharge information Antibiotics Co-amoxiclav 625mg x 3 a day Ciprofloxacin 750mg x 2 a day You will be seen on at To be taken for total 7 days (including hospital stay) 5
A Care Pathway exists for the management of neutropenic fever. Copies of the care pathway document are available in EAU, A&E, Deanesly and CHU.
Subject: Neutropenic Fever Guideline for Junior Doctors Date of Implementation: January 2010 Date of Review: January 2012 Director Responsible for Implementation and Review: Policy location: Consultant
More informationNeutropenic Sepsis Acute General Management and Support. Ernie Marshall Macmillan Consultant in Medical Oncology Clatterbridge Centre for Oncology
Neutropenic Sepsis Acute General Management and Support Ernie Marshall Macmillan Consultant in Medical Oncology Clatterbridge Centre for Oncology Who Am I? I am A Medical Oncologist (MCCN) Site specialist
More informationNEUTROPENIC SEPSIS IN ADULT PATIENTS. Consultant Clinical Oncologist CLINICAL GUIDELINE
Lancashire Teaching Hospitals NHS Foundation Trust NEUTROPENIC SEPSIS IN ADULT PATIENTS KEY WORDS (To assist in searching for the Guideline on the Intranet suggested minimum 10 words ) REF NO: Neutropenic
More informationEmergency Department Overcrowding: Is Ambulatory Care the solution?
Emergency Department Overcrowding: Is Ambulatory Care the solution? Tim Cooksley Consultant in Acute Medicine, UHSM and Honorary Consultant, The Christie @acutemed2 Overview ED Overcrowding The benefit
More informationCLINICAL GUIDELINE FOR MANAGEMENT OF NEUTROPENIC SEPSIS IN ADULT CANCER PATIENTS (this guideline excludes haematology patients)
CLINICAL GUIDELINE FOR MANAGEMENT OF NEUTROPENIC SEPSIS IN ADULT CANCER PATIENTS (this guideline excludes haematology patients) 1. Aim/Purpose of this Guideline 1.1. Systemic cancer treatments and immunological
More informationReducing the Door to Needle Time for Antibiotics in Suspected Neutropenic Sepsis using a Dedicated Clinical Pathway
Reducing the Door to Needle Time for Antibiotics in Suspected Neutropenic Sepsis using a Dedicated Clinical Pathway Dr Alex Williams, Oncology Specialty Doctor. Cheltenham General Hospital Oncology Centre
More informationProtocol for the Management of Neutropenic Sepsis in Adult Patients P
Protocol for the Management of Neutropenic Sepsis in Adult Patients P Version 2 Date April 2015 Review Date April 2016 Author Rachel Onions Change Approver Acute Oncology Team UHMBT. Version 2. CHANGE
More informationCARE PATHWAY FOR CHILDREN AND YOUNG PERSONS WITH FEBRILE NEUTROPENIA, NEUTROPENIC SEPSIS OR SUSPECTED CENTRAL VENOUS LINE INFECTIONS
CARE PATHWAY FOR CHILDREN AND YOUNG PERSONS WITH FEBRILE NEUTROPENIA, NEUTROPENIC SEPSIS OR SUSPECTED CENTRAL VENOUS LINE INFECTIONS This Care Pathway has been developed by a multidisciplinary team. It
More informationPAEDIATRIC FEBRILE NEUTROPENIA CARE PATHWAY
PAEDIATRIC FEBRILE NEUTROPENIA CARE PATHWAY Purpose: This document is intended as a guide to the investigation and management of children presenting in Salisbury District Hospital with suspected neutropenic
More informationAntimicrobial Management of Febrile Neutropenic Sepsis
Antimicrobial Management of Febrile Neutropenic Sepsis Written by: Dr J Joseph, Consultant Haematologist Dr K Gajee, Consultant Microbiologist Amended by: Larissa Claybourn, Antimicrobial Pharmacist Date:
More informationChildren who are neutropenic and unwell, even if normothermic, should be assumed to have infection and be treated appropriately.
PAEDIATRIC FEBRILE NEUTROPENIA CARE PATHWAY Purpose: This document is intended as a guide to the investigation and management of children presenting in Salisbury District Hospital with suspected neutropenic
More informationWhat is Acute Oncology? Kay McCallum Acute Oncology Advanced Nurse Practitioner John Radcliffe Hospital Oxford September 2015
What is Acute Oncology? Kay McCallum Acute Oncology Advanced Nurse Practitioner John Radcliffe Hospital Oxford September 2015 What is Acute Oncology? Outline of Talk Concept of Acute Oncology Service (AOS)
More informationHigh Intensity Chemotherapy Guidelines for Haematology Patients at ASPH
High Intensity Chemotherapy Guidelines for Haematology Patients at ASPH Contents: Page No. 1. Overview 2 2. Admission 3 3. Admission Checklist 5 4. Inpatient management during chemotherapy 6 5. Inpatient
More informationAcute Oncology Martin Eatock Consultant Medical Oncologist NICaN Medical Director
Acute Oncology 2014 Martin Eatock Consultant Medical Oncologist NICaN Medical Director Patients admitted with cancer have a longer than average stay Berger et al. Clin Medicine (2013) Questions If your
More informationShannon Carty, PGY-2 ICCR IRB Project Proposal April 9, 2008
Shannon Carty, PGY-2 ICCR IRB Project Proposal April 9, 2008 Study Title: Observational Study to Determine the Effect of an Emergency Department Adult Oncology Stat Antibiotic Protocol on Clinical Outcomes
More informationGuidelines on the Management of a Child with Sickle Cell Disease and low Haemoglobin
Guidelines on the Management of a Child with Sickle Cell Disease and low Haemoglobin Version: 6 Date: 2 nd March 2010 Authors: Responsible committee or Director: Review date: Target audience: Stakeholders/
More informationNeutropenic Sepsis Guideline
Neutropenic Sepsis Guideline Neutropenic Sepsis Guideline - definitions Suspected or proven infection in a neutropenic patient is a MEDICAL EMERGENCY and is an indication for immediate assessment and prompt
More informationSupplemental Online Case Discussion: Febrile Neutropenia
Supplemental Online Case Discussion: Febrile Neutropenia Alison C. Young, Fiona J. Collinson St James s Institute of Oncology, St James s University Hospital, Leeds, West Yorkshire, United Kingdom Case
More informationThe Role of Observation Care in the Evaluation and Management of Cancer Emergencies
The Role of Observation Care in the Evaluation and Management of Cancer Emergencies Adam Klotz, MD Associate Attending Physician Memorial Sloan Kettering Cancer Center FACULTY DISCLOSURE Nothing to disclose
More informationGuideline for the Use of Granulocyte Colony Stimulating Factor (G-CSF) for Adults in Oncology and Haematology
(G-CSF) for Adults in Oncology and Haematology For Use in: By: Oncology and Haematology Inpatients and Outpatients Oncologists and Haematologists For: Division responsible for document: Key words: Name
More informationGuidelines on the Management of a Child with Sickle Cell Disease and low Haemoglobin
Guidelines on the Management of a Child with Sickle Cell Disease and low Haemoglobin Document Information Version: 2 Date: 28 th December 2013 Authors (incl. job title): Professor David Rees (Consultant
More informationFOLFIRINOX (Irinotecan, Oxaliplatin & infusional Fluorouracil) Cumbria, Northumberland, Tyne & Wear Area Team
DRUG ADMINISTRATION SCHEDULE Day Drug Dose Route Diluent & Rate Glucose 5% 250ml Infusion Fast Running for Line Flush Day 1 Ondansetron 8mg IV bolus Via dextrose drip Dexamethasone 8mg IV bolus Via dextrose
More informationAntimicrobial Guidelines for the Empirical Management of Diabetic Foot Infections
Antimicrobial Guidelines for the Empirical Management of Diabetic Foot Infections Version 7.2 PAGL Inclusion Approved at January 2017 PGC APPROVED BY: TRUST REFERENCE: B3/2017 AWP REF: UHL Policies and
More informationTrust Guideline for the Management of: Condition or Procedure in Adults and / or Children
Trust Guideline for the Management of: Condition or Procedure in Adults and / or Children A clinical guideline recommended For use in: By: For: Division responsible for document: Key words: Name of document
More informationWhat is a TURBT? Removal of an abnormal area within the bladder which may, or may not, prove to be cancer.
What is a TURBT? Removal of an abnormal area within the bladder which may, or may not, prove to be cancer. What are the benefits of this operation? Removal of an abnormality which is sent for analysis
More informationPerformance of a modified MASCC index score for identifying low-risk febrile neutropenic cancer patients
DOI 10.1007/s00520-007-0347-3 ORIGINAL ARTICLE Performance of a modified MASCC index score for identifying low- febrile neutropenic cancer patients Luciano de Souza Viana & José Carlos Serufo & Manoel
More informationStudy No: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStuart Murdoch Consultant Intensive Care St. James s University Hospital March 2010
Stuart Murdoch Consultant Intensive Care St. James s University Hospital March 2010 Background- Critical Care Critical Care originated in Denmark with Polio epidemic 1950s respiratory support alone Rapid
More informationDAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES
DAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES DISCLAIMER: This Clinical Practice Guideline (CPG) generally describes a recommended course of treatment for patients with the identified health
More informationAcute Oncology: Service Provision in Smaller Cancer Centres Ernie Marshall Clatterbridge Centre for Oncology
Acute Oncology: Service Provision in Smaller Cancer Centres Ernie Marshall Clatterbridge Centre for Oncology Whiston Hospital St Helen s Hospital 350,000 population ~1000 beds Regional Plastics Unit DGH
More informationGUIDELINE FOR THE MANAGEMENT OF ANTIBIOTIC- ASSOCIATED DIARRHOEA IN ADULTS
GUIDELINE FOR THE MANAGEMENT OF ANTIBIOTIC- ASSOCIATED DIARRHOEA IN ADULTS Version 3.0 Date ratified May 2008 Review date May 2010 Ratified by NUH Antibiotic Guidelines Committee NUH Drugs and Therapeutics
More informationGASTRO-INTESTINAL TRACT INFECTIONS - ANTIMICROBIAL MANAGEMENT
GASTRO-INTESTINAL TRACT INFECTIONS - ANTIMICROBIAL MANAGEMENT Name & Title Of Author: Dr Linda Jewes, Consultant Microbiologist Date Amended: December 2016 Approved by Committee/Group: Drugs & Therapeutics
More informationGemcitabine + Capecitabine (ESPAC-4 Trial)
Gemcitabine + Capecitabine (ESPAC-4 Trial) European Study Group For Pancreatic Cancer - Trial 4. Combination versus single agent chemotherapy in resectable pancreatic ductal and ampullary cancers. ***
More informationDAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES
DAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES DISCLAIMER: This Clinical Practice Guideline (CPG) generally describes a recommended course of treatment for patients with the identified health
More informationHome intravenous and intramuscular antibiotics
Home intravenous and intramuscular antibiotics Children s Community Nursing Service 0161 206 2370 All Rights Reserved 2018. Document for issue as handout. This booklet has been given to you because your
More informationAbemaciclib (Verzenios ) Abemaciclib (Verzenios )
Abemaciclib (Verzenios ) Abemaciclib (Verzenios ) Abemaciclib is a targeted (biological) therapy. This group of drugs block the growth and spread of cancer. They target and interfere with processes in
More informationBendamustine. Bendamustine. Your treatment Your doctor or nurse clinician has prescribed a course of treatment with bendamustine.
Bendamustine Bendamustine This leaflet is offered as a guide to you and your family. The possible benefits of treatment vary; for some people chemotherapy may reduce the risk of the cancer coming back,
More informationSepsis in primary care. Sarah Bailey, Emma Evans, Nicola Shoebridge, Fiona Wells
Sepsis in primary care Sarah Bailey, Emma Evans, Nicola Shoebridge, Fiona Wells sepsisnurses@uhcw.nhs.uk Quiz!! OR Hands on your heads Hands on your hips Definition. The Third International Consensus Definition
More informationProtocol for Management of Neutropenic Sepsis in Adult Patients within the First 24 hours of Presentation
Protocol for Management of Neutropenic Sepsis in Adult Patients within the First 24 hours of Version One Date of Publication: May 2010 Original Author(s): Carole Connor Nurse Consultant Dr Beth Harrison
More informationNeutropenic sepsis: prevention and management of neutropenic sepsis in cancer patients
Clinical Guideline Neutropenic sepsis: prevention and management of neutropenic sepsis in cancer patients Draft Guideline Neutropenic sepsis: full guideline DRAFT (February 0) Page of Neutropenic sepsis:
More informationDERBY-BURTON CANCER NETWORK CONTROLLED DOC NO:
OBINUTUZUMAB+CHLORAMBUCIL Regimen RDH; Day 1 and 2 Dose to be given on Ward Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community
More informationPrognostic evaluation of febrile neutropaenia in apparently stable adult cancer patients
British Journal of Cancer (2011) 105, 612 617 All rights reserved 0007 0920/11 www.bjcancer.com Prognostic evaluation of febrile neutropaenia in apparently stable adult cancer patients A Carmona-Bayonas*,1,JGómez
More informationReference No: SG 23/13
Title: Author(s) Ownership: Approval by: Guidelines for the use of granulocyte colony stimulating factor (GSCF) in adult oncology & malignant haematology patients Paula Scullin, Consultant Medical Oncologist,
More informationYOUR OPERATION EXPLAINED
RIGHT HEMICOLECTOMY This leaflet is produced by the Department of Colorectal Surgery at Beaumont Hospital supported by an unrestricted grant to better Beaumont from the Beaumont Hospital Cancer Research
More informationADULT (>16) ACUTE SICKLE PAIN GUIDELINE
ADULT (>16) ACUTE SICKLE PAIN GUIDELINE ID 2013 065 Author s Name Dr Anna Wood Author s Job Title Consultant Haematologist Division Consultant Haematologist Department Haematology Version number 3 Ratifying
More informationBrentuximab vedotin. Brentuximab vedotin
Brentuximab vedotin Brentuximab vedotin This leaflet is offered as a guide to you and your family. The possible benefits of treatment vary; for some people chemotherapy may reduce the risk of the cancer
More informationAcute Oncology. Protocols & Competencies Acute Oncology Introduction
Acute Oncology Protocols & Competencies Acute Oncology Introduction Acute Oncology elearning Module Throughout the Acute Oncology FACTS elearning courses you will be able to access Network Protocols by
More informationAcute painful crisis in patients with sickle cell disease: Clinical Guidelines (HN-506a)
Acute painful crisis in patients with sickle cell disease: Clinical Guidelines (HN-506a) Introduction The majority of acute painful crises in patients with sickle cell disease will be managed independently
More informationLifting the lid on a difficile problem part 2 (Clinical) Evidence Based Practice. Problem in evolution (1) Problem in evolution (1) Interventions (2)
Lifting the lid on a difficile problem part (Clinical) Dr Philip T Mannion Consultant Microbiologist, Rhyl Evidence Based Practice Antibiotic prescribing guidance Isolation policy Hand hygiene (soap and
More informationHigh dose cytarabine (Lymphoma)
High dose cytarabine High dose cytarabine (Lymphoma) This leaflet is offered as a guide to you and your family. The possible benefits of treatment vary; for some people chemotherapy may reduce the risk
More informationEffect of Outpatient Treatment of Febrile Neutropenia on the Risk Threshold for the Use of CSF in Patients with Cancer Treated with Chemotherapy
Blackwell Science, LtdOxford, UKVHEValue in Health1098-30152005 ISPOR814752Original ArticleOutpatient Treatment of Febrile NeutropeniaCosler et al. Volume 8 Number 1 2005 VALUE IN HEALTH Effect of Outpatient
More informationPATHWAY MANAGEMENT OF METASTATIC SPINAL CORD COMPRESSION (MSCC) THE CHRISTIE, GREATER MANCHESTER & CHESHIRE
PATHWAY MANAGEMENT OF METASTATIC SPINAL CORD COMPRESSION (MSCC) THE CHRISTIE, GREATER MANCHESTER & CHESHIRE Procedure Reference: Document Owner: Dr V. Misra Version: Accountable Committee: V3 MSCC Network
More informationProphylaxis of febrile neutropenia :experiences with adjuvant TAC
Prophylaxis of febrile neutropenia :experiences with adjuvant TAC 30 th Apr, 2016 Jihyoun Lee Breast center, Department of Surgery Soonchunhyang University Hospital Chemotherapy and the risk of febrile
More informationLow risk upper GI bleeding pathway
Low risk upper GI bleeding pathway Background Low risk upper GI bleeding may be safely managed without an emergency admission to NUH following presentation to the ED. NUH uses the Glasgow Blatchford score
More informationTitle Management of Fever and Neutropenia (Neutropenic Sepsis) in Paediatric Oncology Patients presenting to NDDH Guidelines. Author s job title
Document Control Title Management of Fever and Neutropenia (Neutropenic Sepsis) in Paediatric Oncology Patients presenting to NDDH Guidelines Author Consultant Microbiologist Consultant Paediatrician Consultant
More informationInformation about having a TACE Procedure (Transarterial Chemoembolisation)
Diagnostic Imaging Information about having a TACE Procedure (Transarterial Chemoembolisation) 2 What is a Transarterial Chemoembolisation (TACE) procedure? TACE is a treatment for liver cancer, which
More informationSepsis in primary care. what is good care?
Sepsis in primary care @SepsisUK what is good care? Emmanuel Nsutebu Consultant Infectious Disease Physician & Clinical lead for sepsis Tropical and Infectious Disease Unit Royal Liverpool Hospital Do
More informationGuidelines for the use of G-CSF in the Department of Oncology
Guidelines for the use of G-CSF in the Department of Oncology Full Title of Guideline: Author (include email and role): Division & Speciality: Scope (Target audience, state if Trust wide): Review date
More informationNew Medicines Committee Briefing. July Fosfomycin trometamol for the treatment of multidrug resistant urinary tract infection
New Medicines Committee Briefing July 2014 Fosfomycin trometamol for the treatment of multidrug resistant urinary tract infection (unlicensed indication) Fosfomycin trometamol to be reviewed for use within:
More informationAnterior Cervical Discectomy and Fusion for Cervical Radiculopathy or Cervical Myelopathy (ACDF)
Anterior Cervical Discectomy and Fusion for Cervical Radiculopathy or Cervical Myelopathy (ACDF) About your condition The pressure from your bulging disc(s) might be causing your pain, numbness or weakness.
More informationDALACIN C PHOSPHATE Injection Clindamycin phosphate
DALACIN C PHOSPHATE Injection Clindamycin phosphate Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about Dalacin C Phosphate injection. It does not contain
More informationCetuximab in Combination with Irinotecan based Chemotherapy for the 1 st, 2 nd and 3 rd treatment Metastatic of Colorectal Cancer
Cetuximab in Combination with Irinotecan based Chemotherapy for the 1 st, 2 nd and 3 rd treatment Metastatic of Colorectal Cancer DRUG ADMINISTRATION SCHEDULE Day Drug Daily Dose Route Diluent and rate
More informationPathology Service User Guide Haematology
Pathology Service User Guide Haematology St Richard s This section of the Pathology Service User Guide includes: Anticoagulant Therapy Information about the Anticoagulant Clinic Low Molecular Weight Heparin
More informationSystemic management of pancreatic cancer: Supportive care
Systemic management of pancreatic cancer: Supportive care Snežana Bošnjak Institute for Oncology and Radiology of Serbia Dept. Supportive Oncology & Palliative Care Serbia, Belgrade Integrative Oncology
More informationOutpatient care for patients with neutropenia. Information for patients Weston Park Hospital
Outpatient care for patients with neutropenia Information for patients Weston Park Hospital page 2 of 8 Information for patients who have neutropenia and are going home with oral antibiotics. What is neutropenia?
More informationDrafting a Coverage Authorization Request Letter
Drafting a Coverage Authorization Request Letter The following information is presented for informational purposes only and is not intended to provide reimbursement or legal advice. Laws, regulations,
More informationSafety, feasibility and efficacy of outpatient management of moderate pneumonia at Port Moresby General Hospital: a prospective study
Safety, feasibility and efficacy of outpatient management of moderate pneumonia at Port Moresby General Hospital: a prospective study Dr Rose Morre Master of Medicine research project, 2017 Aim To trial
More informationIntravenous anti-cancer treatment
Intravenous anti-cancer treatment Information for patients Chemotherapy Name Hospital No Your consultant is Anti-cancer treatment is the term used to describe medicines used to treat cancer including chemotherapy.
More informationTuberculosis Procedure ICPr016. Table of Contents
Tuberculosis Procedure ICPr016 Table of Contents Tuberculosis Procedure ICPr016... 1 What is Tuberculosis?... 2 Any required definitions/explanations... 2 NHFT... 2 Tuberculosis (TB)... 3 Latent TB...
More informationUrology and Urinary Tract Infections in Adults
Urology and Urinary Tract Infections in Adults Full Title of Guideline: Author (include email and role): Division & Speciality: Scope (Target audience, state if Trust wide): Review date (when this version
More informationThe McMaster at night Pediatric Curriculum
The McMaster at night Pediatric Curriculum Community Acquired Pneumonia Based on CPS Practice Point Pneumonia in healthy Canadian children and youth and the British Thoracic Society Guidelines on CAP Objectives
More informationPOLICY FOR THE SAFE USE OF ORAL METHOTREXATE IN SECONDARY CARE. September 2011
POLICY FOR THE SAFE USE OF ORAL METHOTREXATE IN SECONDARY CARE September 2011 WHSCT Policy for the safe use of oral methotrexate in secondary care Page 1 of 8 Policy Title Policy for the safe use of oral
More informationNo Catheter, No CAUTI Scenario 1 Urinary catheter-trauma
No Catheter, No CAUTI Scenario 1 Urinary catheter-trauma Course lead Colette Laws-Chapman Faculty Course / Curriculum Scenario name No Catheter, No catheter associated urine infection (CAUTI) Scenario
More informationGuideline for the Management of Acute Chest Syndrome in Children with Sickle Cell Disease
Guideline for the Management of Acute Chest Syndrome in Children with Sickle Cell Disease Definition Acute chest syndrome (ACS) is defined as an acute illness characterized by fever and/or respiratory
More informationFeeling sick? What to do. Information for people with Type 1 Diabetes
Feeling sick? What to do Information for people with Type 1 Diabetes Diabetes and sick days A minor illness can result in a major rise in blood glucose levels Common illnesses such as tonsillitis, ear,
More informationReferral guide for acute oncology emergencies
Referral guide for acute oncology emergencies 1 st Edition v 1.0 London Cancer March 2013 To be used in conjunction with London Cancer clinical guidelines for acute oncology emergencies; A Guide to Acute
More informationViral Infections. 1. Prophylaxis management of patient exposed to Chickenpox:
This document covers: 1. Chickenpox post exposure prophylaxis 2. Chickenpox treatment in immunosuppressed/on treatment patients 3. Management of immunosuppressed exposed to Measles All children with suspected
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationDoctor s Instructions. Patient: Heather Crawford Age: 65 years old. PMH 2012: Hypertension 2014: Diverticular Disease
Doctor s Instructions Patient: Heather Crawford Age: 65 years old PMH 2012: Hypertension 2014: Diverticular Disease Drug History NKDA Amlodipine 5mg OD Actor s Script *The most important things to remember
More informationUrgent and Emergency Care Lung Cancer Initiative
Urgent and Emergency Care Lung Cancer Initiative Dr Gavin Anderson Consultant Physician Hull & East Yorkshire Hospitals NHS Trust Unscheduled Care in Hull & East Riding Background Local evaluation Sociodemographics
More informationIs pre-emptive therapy a realistic approach?
Is pre-emptive therapy a realistic approach? J Peter Donnelly PhD, FRCPath Department of Haematology Radboud University Nijmegen Medical Centre Nijmegen, The Netherlands Is pre-emptive therapy a realistic
More informationFebrile neutropenia. Febrile neutropenia. Febrile neutropenia. Febrile neutropenia 1/30/2019. Infection in patients with cancer
Manit Sae-teaw B.Pharm, BCP, BCOP Glad dip in pharmacotherapy Faculty of pharmaceutical sciences Ubon Ratchathani University Fever Oral temperature measurement of 38.3 C (101.0 F) single 38.0 C (100.4
More informationABVD. by infusion over 30 minutes. You will have treatment on Day 1 and Day 15 (this is one cycle) for 2, 3 or 6 cycles.
ABVD ABVD This leaflet is offered as a guide to you and your family. The possible benefits of treatment vary; for some people chemotherapy may reduce the risk of the cancer coming back, for others it may
More informationTransurethral Resection of Prostate
Transurethral Resection of Prostate Information for Patients This leaflet explains: What does the procedure involve?...2 What are the alternatives to this procedure?...2 What should I expect before the
More informationBladder tumour resection (TURBT): procedure-specific information
PATIENT INFORMATION Bladder tumour resection (TURBT): procedure-specific information What is the evidence base for this information? This leaflet includes advice from consensus panels, the British Association
More informationTEMPLATE CASE REPORT FORM. Rapid Response Pharmacovigilance in Palliative Care
TEMPLATE CASE REPORT FORM Rapid Response Pharmacovigilance in Palliative Care The case report form is to be completed in compliance with PaCCSC Standard Operating Procedures 1 Staff email: Participant
More informationThe Oxford AHSN Sepsis Pathway
From confusion to consensus: The Oxford AHSN Sepsis Pathway Andrew Brent Sepsis Clinical Lead, Oxford AHSN & Oxford University Hospitals NHS Foundation Trust 2013 2014 2015 2016 2017 From: The Third International
More informationPresent-on-Admission (POA) Coding
1 Present-on-Admission (POA) Coding Michael Pine, MD, MBA Michael Pine and Associates, Inc 2 POA and Coding Guidelines (1) Unless otherwise specified, a POA modifier must be assigned to each principal
More informationRed blood cell transfusion
Red blood cell transfusion This leaflet explains more about red blood cell transfusion, including the benefits, risks and any alternatives and what you can expect when you come to hospital. If you have
More informationLaser vaporisation of prostate (Green light laser prostate surgery): procedure-specific information
PATIENT INFORMATION Laser vaporisation of prostate (Green light laser prostate surgery): procedure-specific information What is the evidence base for this information? This leaflet includes advice from
More informationDay care adenotonsillectomy in sleep apnoea
Day care adenotonsillectomy in sleep apnoea Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Day care adenotonsillectomy in presence of sleep apnoea 1a 2a 2b Contact
More informationASPIRATION PNEUMONIA/PARKINSON S
ASPIRATION PNEUMONIA/PARKINSON S MODULE: CORE MEDICINE: CARE OF THE ELDERLY TARGET: FY1/2 CMT 1/2 (+NURSES, SALT, OT & PT) BACKGROUND: Community- acquired pneumonia (CAP) is a major cause of morbidity
More informationYour Medical Details and Treatment Tracker. About You
This document is intended to help you keep a record of important details that you may need to share with healthcare professionals throughout your Living with Neuroendocrine Tumours (NETs) journey. Take
More informationFaster Cancer Treatment Indicators: Use cases
Faster Cancer Treatment Indicators: Use cases 2014 Date: October 2014 Version: Owner: Status: v01 Ministry of Health Cancer Services Final Citation: Ministry of Health. 2014. Faster Cancer Treatment Indicators:
More informationHenoch-Schӧnlein Purpura (HSP) Child Health Patient Information Leaflet
Henoch-Schӧnlein Purpura (HSP) Child Health Patient Information Leaflet Henoch-Schönlein Purpura (HSP) Pronounced "hen-awk shern-line purr-purr-ah" What is Henoch-Schönlein Purpura? HSP causes blood vessels
More informationR-FC for Chronic Lymphocytic Leukaemia LKWOS-005/01
West of Scotland Cancer Network Chemotherapy Protocol R-FC for Chronic Lymphocytic Leukaemia LKWOS-005/01 Indication B cell Chronic Lymphocytic Leukaemia First line therapy in patients under 70 years of
More informationComparison of Meropenem with Ceftazidime as Monotherapy of Cancer Patients with Chemotherapy induced Febrile Neutropenia
Comparison of Meropenem with Ceftazidime as Monotherapy of Cancer Patients with Chemotherapy induced Febrile Neutropenia I. Malik ( National Cancer lnsititute, Karachi ) Shaharyar (, Department of Radiotherapy
More informationTraztuzumab (Herceptin)
Traztuzumab (Herceptin) Information for patients Chemotherapy Name Hospital No Your consultant is Important Advice Always carry your chemotherapy alert card. It is important that you know what to do if
More informationRadical removal of the kidney (radical nephrectomy): procedure-specific information
PATIENT INFORMATION Radical removal of the kidney (radical nephrectomy): procedure-specific information What is the evidence base for this information? This leaflet includes advice from consensus panels,
More informationCEWT (Children s Epilepsy Workstream in Trent) Guidelines process.
ttingham Children s Hospital ttingham University Hospitals Seizure with Fever Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Contact Name and Job Title (author)
More information